• Vaccine Name: rORFV-RHDV-VP60
• Target Pathogen: Rabbit hemorrhagic disease virus
• Target Disease: Rabbit hemorrhagic disease
• Vaccine Ontology ID: VO_0004767
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Rabbit
• ORF1 gene engineering:
  • Type: Recombinant protein preparation
  • Description: Recombinant Orf virus (ORFV; Parapoxvirus) expressing the major capsid protein VP1 (VP60) of the calicivirus, rabbit hemorrhagic disease virus (RHDV) (Rohde et al., 2011).
  • Detailed Gene Information: Click Here.
• Vector:
  • Vector name:
  • VO vector ID: VO_0001108
  • Description: (Rohde et al., 2011)
• Preparation: (Rohde et al., 2011) Anew recombinant Orf virus (ORFV; Parapoxvirus) expressing the major capsid protein VP1 (VP60) of RHDV.
• Immunization Route: Intramuscular injection (i.m.)

Rabbit Response

• Vaccination Protocol: The animals were immunized once, twice or 3-times by the intramuscular (i.m.) route with 1 ml D1701-V-VP1 containing 10^7 PFU (plaque-forming units), 10^6 PFU, or 10^5 PFU, respectively. For controls, groups of rabbits were vaccinated with the commercial RHDV vaccine “RIKA-VACC” (Riemser Arzneimittel AG, Germany) or remained non-vaccinated (Rohde et al., 2011).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: Twenty two days after the last vaccination, the animals were inoculated i.m. with 1 ml containing 104 LD50 (lethal dose 50) of the virulent RHDV strain “Eisenhüttenstadt” (Rohde et al., 2011).
• Efficacy: All animals immunized with the ORFV-vectored vaccine survived without any clinical signs, similar to animals control immunized with the commercially available inactivated RHDV vaccine RIKA-VACC. As expected, all non-immunized rabbits died within 48 h after challenge with RHD-specific clinical symptoms (Rohde et al., 2011).